AVONEX (IFN B1A) IN SUBJECTS AT HIGH RISK FOR DEVELOPMENT OF MULTIPLE SCLEROSIS

Avonex是一种重组人β干扰素产品，是一种抗病毒药物 成纤维细胞被病毒感染诱导后产生的蛋白质。这 随机、双盲、安慰剂对照研究将确定 Avonex有助于延缓临床确诊的多发性心脏病的发病 第一次和最近一次发病的受试者的硬化症 脱髓鞘事件，以及多发性硬化症的高危人群。一个 共有380名受试者将接受Avonex或Avonex的IM治疗 每周服用安慰剂，最长可达三年。 这个中心招收了六名病人，以后不会再有病人了 招聘。对这些患者的随访将继续进行。

AVONEX, a recombinant human interferon-beta product, is an antiviral protein produced by fibroblasts after induction by viral infection. This randomized, double-blinded, placebo-controlled study will determine if AVONEX is beneficial in delaying the onset of clinically definite multiple sclerosis in subjects who have experienced a first and recent onset of a demyelinating event, and who are at high risk for multiple sclerosis. A total of 380 subjects will be treated with IM injections of AVONEX or placebo weekly for up to three years. Six patients were enrolled at this center, and there will be no more recruiting. Followup of these patients will continue.